

Oklo is building a stable U.S. supply of critical radioisotopes

With global supply declining and demand accelerating, Oklo will deliver the nation's first modern, integrated radioisotope supply chain.



Energy & Advanced Industry
Power electronics (silicon doping), semiconductor manufacturing, infrastructure inspection, and subsurface energy exploration.



Defense
Provide reliable, always-on power for national security platforms



Space & National Security
Reliable, long-duration power for spacecraft and defense platforms.



Scientific Research
Materials testing, biology, and nuclear science.




Healthcare
Tumor detection, diagnostic imaging, and targeted treatment.

50 million nuclear-medical procedures are carried out every year




Source: World Nuclear Association

Spotlight on targeted alpha therapy: How it works to help beat cancer



In targeted alpha therapy, a radioactive compound is linked to a targeting molecule that seeks out a specific target protein on a cancer cell. Once bound, the radioactive compound delivers highly potent, short-range alpha radiation directly to the cancer cell, minimizing damage to nearby healthy cells.

Radioisotopes face a global shortage; Oklo has a massive market opportunity



Source: Fact.MR

95% of global Mo-99 comes from a handful of reactors that are potentially within 5-10 years of closing.



Source: NIH

Demand is rising.


By 2035, the nuclear medicine radioisotopes market is expected to be worth almost \$23 billion, driven by the expanding adoption of nuclear medicine in oncology, cardiology, neurology, and theranostics.

Supply is constrained.

Most radioisotopes are produced in a small number of aging research reactors, largely outside the United States. Many were built before 1975 and are expected to retire within the next decade, limiting future supply.

What happens if there is a radioisotope shortage?

Delayed scans and cancer treatments, bottlenecked semiconductor and materials testing, constrained development of new cancer therapies, and increased risk in other critical experiments.



Oklo is already advancing multiple sites to build domestic radioisotope production

Pilot	Demonstration	Commercial	Commercial
Idaho Radioisotopes Laboratory	Texas Groves pilot facility	Idaho Meitner-1: Multi-Reactor Radioisotope Foundry	Oak Ridge Advanced Nuclear Fuel Recycling Facility
De-risk and accelerate	Streamline construction	Scale domestic supply	Expand output
Generate early isotope output at this U.S. Nuclear Regulatory Commission-approved laboratory, build operational experience, and bridge the gap from pilot validation to commercial production.	Demonstrate rapid reactor deployment by demonstrating criticality in under 1 year under the DOE Reactor Pilot Program.	Deliver sustained, commercial-scale radioisotope production for healthcare, industry, research, and national security.	Extract high-value isotopes during advanced fuel recycling. This integrates isotope production into the fuel cycle and expands long-term domestic supply.
Timing: 2026	Timing: 2026–2027	Timing: 2027+	Timing: 2030+